Ayala Pharmaceuticals, Inc. (ADXS)
ADXS Stock Price Chart
Explore Ayala Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze ADXS price movements and trends.
ADXS Company Profile
Discover essential business fundamentals and corporate details for Ayala Pharmaceuticals, Inc. (ADXS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 May 2020
Employees
20.00
Website
https://www.ayalapharma.comCEO
Kenneth A. Berlin
Description
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
ADXS Financial Timeline
Browse a chronological timeline of Ayala Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 5 Jun 2025
Earnings released on 29 May 2025
Earnings released on 27 Mar 2025
Earnings released on 24 Dec 2024
Earnings released on 26 Sept 2024
Earnings released on 16 Apr 2024
Earnings released on 12 Feb 2024
EPS came in at -$4.10 falling short of the estimated -$1.27 by -222.77%.
Earnings released on 20 Nov 2023
EPS came in at -$1.53 falling short of the estimated -$1.27 by -20.78%.
Earnings released on 25 Sept 2023
EPS came in at -$1.82 surpassing the estimated -$2.19 by +16.84%, while revenue for the quarter reached $9.00K .
Earnings released on 28 Jun 2023
EPS came in at -$1.67 , while revenue for the quarter reached $4.00K .
Earnings released on 15 Mar 2023
EPS came in at -$5.27 , while revenue for the quarter reached $105.00K .
Earnings released on 10 Feb 2023
EPS came in at -$2.53 falling short of the estimated -$0.73 by -246.58%, while revenue for the quarter reached $250.00K .
Earnings released on 12 Sept 2022
EPS came in at -$3.83 falling short of the estimated -$3.20 by -19.69%, while revenue for the quarter reached $38.00K .
Earnings released on 8 Jun 2022
EPS came in at -$1.90 surpassing the estimated -$3.20 by +40.63%, while revenue for the quarter reached $250.00K .
Stock split effective on 6 Jun 2022
Shares were split 1 : 80 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 17 Mar 2022
EPS came in at -$2.40 surpassing the estimated -$3.20 by +25.00%, while revenue for the quarter reached $1.15M .
Earnings released on 14 Feb 2022
EPS came in at -$3.20 matching the estimated -$3.20, while revenue for the quarter reached $625.00K .
Earnings released on 10 Sept 2021
EPS came in at -$1.60 falling short of the estimated -$1.07 by -50.00%, while revenue for the quarter reached $761.00K .
Earnings released on 14 Jun 2021
EPS came in at -$3.20 falling short of the estimated -$0.05 by -6.30K%, while revenue for the quarter reached $974.00K , missing expectations by -40.97%.
Earnings released on 25 Jan 2021
EPS came in at -$6.40 , while revenue for the quarter reached $1.00M .
Earnings released on 22 Jan 2021
EPS came in at -$7.37 , while revenue for the quarter reached $658.00K .
Earnings released on 10 Sept 2020
EPS came in at -$7.20 falling short of the estimated -$0.15 by -4.70K%, while revenue for the quarter reached $1.05M .
ADXS Stock Performance
Access detailed ADXS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.